Vistagen Therapeutics CFO Resignation and Annual Meeting Results

Vistagen Therapeutics, Inc. announced the resignation of its Chief Financial Officer, Cynthia L. Anderson, effective October 15, 2025. Anderson's resignation is not due to any disagreement with the company. The company is searching for a successor and plans to enter into a consulting agreement with Anderson to assist with the transition. Additionally, the company held its 2025 Annual Meeting of Stockholders on September 9, 2025. During the meeting, stockholders elected six directors to the Board, approved executive compensation on an advisory basis, and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026.